Dr Brendan Johnson

Dr Brendan Johnson

Principal clinical pharmacokineticist
GlaxoSmithKline, USA
Bachelor of Pharmacy 1997,
Bachelor of Pharmaceutical Science (Honours) 1999, PhD 2003

I support drug development in oncology and was a lead author of the clinical pharmacology package for a new drug to prevent nausea and vomiting, associated with chemotherapy.

I took up a postdoctoral position in 2003 at the University of North Carolina and GlaxoSmithKline, where I designed, conducted and analysed clinical pharmacokinetic studies that examined biliary excretion of drugs in humans. At GSK, I focus on advanced methods of pharmacokinetic and pharmacodynamic  data analysis and modelling techniques.

I now work in the GSK Clinical Pharmacology Modelling and Simulation group, facilitating drug development and influencing decision making such as Phase III dose selection and clinical-trial design.